Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acetohydroxamic Acid

FDA-approved product (tablet, oral), marketed as Lithostat.

Registered studies
5
Lab records
2
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Acetohydroxamic Acid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other urologicals
FDA pharmacologic class
Urease Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Acetohydroxamic Acid, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA1.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli3.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis6.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 0 of 1 lab record
  • E. coli: measured active in 0 of 1 lab record
Open Acetohydroxamic Acid in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acetohydroxamic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

    NCT07393438 · start 2026-02-21

    Registered record
    Registry ID
    NCT07393438
    Conditions
    Multidrug-Resistant Tuberculosis; Rifampicin-resistant Tuberculosis; MDR-TB; RR-TB
    Interventions
    Acetohydroxamic Acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-02-21
    Completion
    2028-11-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug-Resistant Tuberculosis; Rifampicin-resistant Tuberculosis; MDR-TB; RR-TB
    InterventionAcetohydroxamic Acid; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults

    NCT05908825 · start 2023-06-22

    Registered record
    Registry ID
    NCT05908825
    Conditions
    Photodamaged Skin
    Interventions
    Vitamin C with AHA Exfoliative Serum; Placebo serum
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-06-22
    Completion
    2024-01-26
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhotodamaged Skin
    InterventionVitamin C with AHA Exfoliative Serum; Placebo serum
    PhaseNot applicable
    Registry statusCompleted

  • Manipulating the Gut Microbiome Study

    NCT03181828 · start 2017-03-24

    Registered record
    Registry ID
    NCT03181828
    Conditions
    Urea Cycle Disorder
    Interventions
    Acetohydroxamic Acid Oral Tablet; No treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2017-03-24
    Completion
    2018-06-05
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrea Cycle Disorder
    InterventionAcetohydroxamic Acid Oral Tablet; No treatment
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • MyHeart Counts Cardiovascular Health Study

    NCT03090321 · start 2015-03

    Registered record
    Registry ID
    NCT03090321
    Conditions
    Cardiovascular Health
    Interventions
    Stand Prompt; Step Prompt; Cluster Prompt; Read AHA website
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2015-03
    Completion
    2029-12
    Enrolment
    2,000,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Health
    InterventionStand Prompt; Step Prompt; Cluster Prompt; Read AHA website
    PhaseNot applicable
    Registry statusActive not recruiting

  • Acute High-risk Abdominal Surgery Study - an Optimized Perioperative Course

    NCT01899885 · start 2013-06

    Registered record
    Registry ID
    NCT01899885
    Conditions
    Perforated Viscus; Intestinal Obstruction
    Interventions
    AHA (Acute Highrisk Abdominalsurgery): Optimized Course
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerforated Viscus; Intestinal Obstruction
    InterventionAHA (Acute Highrisk Abdominalsurgery): Optimized Course
    PhaseNot applicable
    Registry statusCompleted